Hemogenyx Pharmaceuticals PLC Announces CBR Macrophage Delivery Update
Hemogenyx Pharmaceuticals has announced a breakthrough in delivering Chimeric Bait Receptors (CBR) to innate immune cells. The company has developed a novel method using lentiviral vectors to achieve highly efficient transduction of macrophages and monocytes, while maintaining durable CBR expression in these cells.
This innovative approach will extend both the efficacy and durability of CBR within transduced cells, significantly accelerating the development of CBR-based product candidates. The company plans to advance new CBR-based product candidates into clinical trials once sufficient resources are secured, aiming to address unmet medical needs.
Hemogenyx Pharmaceuticals ha annunciato una svolta nella somministrazione dei Recettori di Esca Chimerici (CBR) alle cellule immunitarie innate. L'azienda ha sviluppato un metodo innovativo utilizzando vettori lentivirali per ottenere una trasduzione altamente efficiente di macrofagi e monociti, mantenendo allo stesso tempo un'espressione duratura dei CBR in queste cellule.
Questo approccio innovativo aumenterà sia l'efficacia che la durata dei CBR all'interno delle cellule trasdotte, accelerando significativamente lo sviluppo di candidati a base di CBR. L'azienda prevede di avanzare nuovi candidati a base di CBR in sperimentazioni cliniche una volta assicurate risorse sufficienti, con l'obiettivo di soddisfare bisogni medici non soddisfatti.
Hemogenyx Pharmaceuticals ha anunciado un avance en la entrega de Receptores de Cebo Quiméricos (CBR) a las células inmunitarias innatas. La empresa ha desarrollado un método novedoso utilizando vectores lentivirales para lograr una transducción altamente eficiente de macrófagos y monocitos, manteniendo al mismo tiempo una expresión duradera de CBR en estas células.
Este enfoque innovador ampliará tanto la eficacia como la durabilidad de los CBR dentro de las células transducidas, acelerando significativamente el desarrollo de candidatos a base de CBR. La empresa planea avanzar nuevos candidatos a base de CBR a ensayos clínicos una vez que se aseguren suficientes recursos, con el objetivo de abordar necesidades médicas insatisfechas.
Hemogenyx Pharmaceuticals는 자연 면역 세포에 Chimeric Bait Receptors (CBR)를 전달하는 획기적인 방법을 발표했습니다. 이 회사는 렌티바이러스를 이용한 새로운 방법을 개발하여 대식세포와 단핵구의 높은 효율적인 전이(transduction)를 달성하였으며, 이러한 세포에서 CBR의 지속적인 발현을 유지하고 있습니다.
이 혁신적인 접근법은 전환된 세포 내에서 CBR의 효능과 내구성을 모두 연장하여 CBR 기반의 제품 개발을 크게 가속화할 것입니다. 이 회사는 충분한 자원이 확보되면 새로운 CBR 기반 제품 후보를 임상 시험에 진입시킬 계획이며, 이는 충족되지 않은 의료 필요를 해결하는 것을 목표로 하고 있습니다.
Hemogenyx Pharmaceuticals a annoncé une avancée dans la livraison des Récepteurs de Bait Chimiques (CBR) aux cellules immunitaires innées. L'entreprise a développé une nouvelle méthode utilisant des vecteurs lentiviraux pour réaliser une transduction hautement efficace des macrophages et des monocytes, tout en maintenant une expression durable des CBR dans ces cellules.
Cette approche innovante permettra d'étendre à la fois l'efficacité et la durabilité des CBR au sein des cellules transduites, accélérant ainsi de manière significative le développement des candidats de produits basés sur les CBR. L'entreprise prévoit de faire progresser de nouveaux candidats à base de CBR vers des essais cliniques une fois que des ressources suffisantes auront été sécurisées, visant à répondre aux besoins médicaux non satisfaits.
Hemogenyx Pharmaceuticals hat einen Durchbruch bei der Bereitstellung von Chimeric Bait Receptors (CBR) an innate Immunzellen angekündigt. Das Unternehmen hat ein neuartiges Verfahren entwickelt, das lentivirale Vektoren nutzt, um eine hoch effiziente Transduktion von Makrophagen und Monozyten zu erreichen, während die dauerhafte CBR-Expression in diesen Zellen aufrechterhalten wird.
Dieser innovative Ansatz wird sowohl die Wirksamkeit als auch die Haltbarkeit von CBR in transduzierten Zellen verlängern und somit die Entwicklung von CBR-basierten Produktkandidaten erheblich beschleunigen. Das Unternehmen plant, neue CBR-basierte Produktkandidaten in klinische Studien voranzubringen, sobald ausreichend Ressourcen gesichert sind, mit dem Ziel, nicht erfüllte medizinische Bedürfnisse zu adressieren.
- Breakthrough in CBR delivery method using lentiviral vectors
- Improved efficacy and durability of CBR in transduced cells
- Acceleration of CBR-based product development timeline
- Development progression contingent on securing additional resources
Breakthrough in Delivering Chimeric Bait Receptors to Immune Cells Accelerates Development
LONDON, UK / ACCESSWIRE / December 6, 2024 / Hemogenyx Pharmaceuticals plc (LSE:HEMO), the clinical-stage biopharmaceutical company, is pleased to announce a breakthrough in its development of a novel method for delivering Chimeric Bait Receptors ("CBR") to innate immune cells such as macrophages and monocytes i.e. the white myeloid blood cells that make up the body's first line of defence against infections and responsible for the removal of diseased or damaged cells. This innovative approach utilizes lentiviral vectors (a laboratory constructed and modified retrovirus that can be used to insert genetic material into cells) to achieve highly efficient transduction of macrophages or monocytes, while maintaining durable, long-lasting CBR expression in these cells. In more simple terms, the new methodology will extend the efficacy as well as the durability of CBR within transduced cells.
The Company believes that this innovative approach to myeloid immune cell transduction will significantly accelerate the development of CBR-based product candidates, facilitating their progression into IND-enabling studies.
The Company's first-class scientific team continues to make good progress with CBR and, once sufficient resources are provided, the Company anticipates moving new CBR-based product candidates into clinical trials, bringing them closer to addressing unmet medical needs.
Dr Vladislav Sandler, CEO & Co-Founder of Hemogenyx Pharmaceuticals, commented: "We are thrilled to announce this critical advancement in our CBR platform, which represents a significant step forward in our mission to develop cutting-edge therapies for unmet medical needs. Overcoming the challenges of efficiently delivering CBRs to myeloid immune cells has been a key focus for our team, and this breakthrough underscores their dedication and ingenuity We remain committed to leveraging this technology to bring transformative therapies to the clinic and, ultimately, to patients in need. Once sufficient resources are available to CBR, we are confident in our ability to translate these scientific breakthroughs into impactful treatments."
Market Abuse Regulation (MAR) Disclosure
Certain information contained in this announcement would have been inside information for the purposes of Article 7 of Regulation No 596/2014 (as it forms part of UK domestic law by virtue of the European Union (Withdrawal) Act 2018) until the release of this announcement.
Enquiries:
Hemogenyx Pharmaceuticals plc | |
Dr Vladislav Sandler, Chief Executive Officer & Co-Founder | |
Peter Redmond, Director | |
|
|
SP Angel Corporate Finance LLP | Tel: +44 (0)20 3470 0470 |
Matthew Johnson, Vadim Alexandre, Adam Cowl |
|
|
|
Peterhouse Capital Limited | Tel: +44 (0)20 7469 0930 |
Lucy Williams, Duncan Vasey, Charles Goodfellow |
|
About Hemogenyx Pharmaceuticals plc
Hemogenyx Pharmaceuticals is a publicly traded company (LSE: HEMO) headquartered in London, with its US operating subsidiaries, Hemogenyx Pharmaceuticals LLC and Immugenyx LLC, located in New York City at its state-of-the-art research facility.
The Company is a clinical-stage biopharmaceutical group developing new medicines and treatments for life-threatening diseases. Hemogenyx Pharmaceuticals is developing several distinct and complementary product candidates, as well as a platform technology that it uses as an engine for novel product development.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
SOURCE: Hemogenyx Pharmaceuticals PLC
View the original press release on accesswire.com
FAQ
What breakthrough did Hemogenyx Pharmaceuticals announce on December 6, 2024?
How will the new CBR delivery method benefit Hemogenyx's development pipeline?
What are the current limitations for Hemogenyx's CBR development progress?
